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ABSTRACT
Nafenopin (2-methyl-2[p-(1,2,3,4-tetrahydro-l-naphthyl)phenoxy]-propionic acid; Su-
13437), a potent hypolipidemic compound, was administered in varying concentrations in
ground Purina Chow to male and female rats, wild type (Csa strain) mice and acatalasemic
(Csb strain) mice to determine the hepatic microbody proliferative and catalase-inducing
effects. In all groups of animals, administration of nafenopin at dietary levels of 0.125%
and 0.25% produced a significant and sustained increase in the number of peroxisomes .
The hepatic microbody proliferation in both male and female rats and wild type Csa strain
mice treated with nafenopin was of the same magnitude and was associated with a two-fold
increase in catalase activity and in the concentration of catalase protein . The increase in
microbody population in acatalasemic mice, although not accompanied by increase in
catalase activity, was associated with a twofold increase in the amount of catalase protein .
The absence of sex difference in microbody proliferative response in nafenopin-treated rats
and wild type mice is of particular significance, since ethyl-a-p-chlorophenoxyisobutyrate
(CPIB)-induced microbody proliferation and increase in catalase activity occurred only in
males. Nafenopin can, therefore, be used as an inducer of microbody proliferation and of
catalase synthesis in both sexes of rats and mice. The serum glycerol-glycerides were
markedly lowered in all the animals given nafenopin, which paralleled the increase in liver
catalase. All the above effects of nafenopin were fully reversed when the drug was with-
drawn from the diet of male rats . During reversal, several microbody nucleoids were seen
free in the hyaloplasm or in the dilated endoplasmic reticulum channels resulting from a
rapid reduction in microbody matrix proteins after the withdrawal of nafenopin from the
diet. Because of microbody proliferation and catalase induction with increasing number of
hypolipidemic compounds, additional studies are necessary to determine the interrelation-
ships of microbody proliferation, catalase induction, and hypolipidemia .
INTRODUCTION
Microbodies (peroxisomes), the cytoplasmic con- liver (2), have only recently been recognized as
stituents described originally in kidney (1) and ubiquitous structures in animal (3-5) and plant
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the biochemical composition of microbodies of
rat liver and showed that these structures possess
catalase and several oxidative enzymes. It is
evident from several studies that catalase is the
only constant component of peroxisomes derived
from different sources, whereas the hydrogen
peroxide-generating oxidative enzymes that are
associated with catalase differ in number and in
specificity (9) . On the basis of the cytochemical
localization of catalase with the alkaline 3', 3'-
diaminobenzidine medium (10, 11), microbodies
have been identified in tissues other than liver
and kidney. Additional studies, however, are
necessary to characterize the composition of these
catalase-containing structures in tissues other
than liver and kidney either by biochemical or
cytochemical procedures ; and if the structures are
found to possess at least one hydrogen peroxide-
producing oxidase, they can then be unequivo-
cally regarded as peroxisomes .
Although considerable progress has been made
in the understanding of the functional role of
peroxisomes in plant cells, the importance of these
organelles in cellular metabolism in animal tissues
remains to be elucidated . However, several studies
suggest that microbodies may play a significant
but as yet unexplained role in a variety of func-
tions such as in gluconeogenesis, in cholesterol
and steroid metabolism, in the detoxification of
hydrogen peroxide, etc . (7, 12, 13) . Studies with
ethyl-cY p-chlorophenoxyisobutyrate (CPIB) have
clearly established that this compound is valuable
in investigating the biological behavior of micro-
bodies under different experimental situations
and also suggested a possible relationship between
microbodies and lipid metabolism (13-18) . CPIB
is a potent hypolipidemic drug which lowers
serum triglycerides and cholesterol in man (19)
and in experimental animals (20) . Administration
of this drug to male rats results in a significant
increase in the number of microbody profiles in
liver cells (14-16) . The CPIB-induced microbody
proliferation in male rat liver was associated with
a marked increase in catalase activity resulting
from enhanced rate of synthesis of this enzyme
(21). However, when CPIB was administered to
female rats in doses identical to those given to
male rats for the same duration, there was no
appreciable increase either in the number of
microbody profiles or in the liver catalase activity .
Similar sex differences in microbody proliferative
and catalase response were observed in C3H mice
and in wild type (Csa strain) mice given CPIB,
whereas no sex difference in microbody prolifera-
tive response was noted in acatalasemic (Csb
strain) mice (17).
Recently we have demonstrated that adminis-
tration of nafenopin (2-methyl-2[p-(l,2,3,4-
tetrahydro-l-nephthyl)phenoxy]-propionic acid;
Su-13437) to male rats, by gavage at 100 mg/kg
body weight daily for 1-2 wk, results in a marked
proliferation of hepatic microbody profiles with
simultaneous increase in catalase activity (22).
Nafenopin is structurally related to CPIB and on
an equivalent weight basis is approximately five
times as potent as CPIB in producing hypo-
lipidemia and hepatomegaly (23, 24) . In the
present investigation varying concentrations of
nafenopin were administered in ground Purina
Chow ad lib to both male and female rats, wild
type (Csa strain) mice and acatalasemic (Cs'
strain) mice, in order to determine the dose-
response relationship and to ascertain the species
and sex differences, if any, in microbody prolifera-
tive response and inducibility of liver catalase .
The results indicate an absence of sex difference
in microbody proliferative response in nafenopin-
treated rats and wild mice, whereas CPIB-induced
microbody proliferation occurred only in males
(16) . Accordingly, nafenopin can be used as an
inducer of microbody proliferation and of catalase
enzyme synthesis in both sexes of rats and mice .
These studies also emphasize the significance of
hypolipidemic drugs as effective tools for investi-
gating the interrelationship of microbodies with
lipid metabolism.
MATERIALS AND METHODS
Animals and Treatment
The inbred rats used in these experiments were of
the F-344 strain (Simonson Laboratories Inc ., Gilroy,
Calif.) weighing between 125 and 175 g, which were
maintained in individual cages . The wild type (Csa
strain) mice and the acatalasemic (Csb strain) mice
used in these experiments were 2-6 mo old and
weighed between 20 and 30 g. Nafenopin (CIBA
Pharmaceuticals, Summit, N. J .) was added to the
ground Purina Chow in concentrations of 0.0125%,
0.05%, 0.125%, and 0.25% and was thoroughly
mixed. Preliminary studies in rats indicated that
nafenopin at 0.125% and 0.25% dietary levels was
very effective in inducing microbody proliferation .
Accordingly, studies in wild type and acatalasemic
mice were conducted with these two dose levels . At
the end of 1, 2, 3, 4, 6, and 8 wk, liver tissue for mor-
phological studies was obtained from two to three
animals from each of the treated groups after laparot-
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345omy or sacrifice. The reversal of nafenopin-induced
microbody proliferation was investigated in male
rats. After receiving 0.25% nafenopin for 6 wk, ani-
mals were killed on days 1, 3, 5, 7, 10, and 14 after
withdrawal of the drug for ultrastructural studies and
catalase assay.
Morphology
For light microscope examination, samples of liver
were fixed in neutral buffered formaldehyde and
embedded in paraffin. 3-5 µm sections were stained
with hematoxylin and eosin. For electron microscope
studies, tissues were fixed for 1-2 h at 4 °C in 2%
osmium tetroxide buffered with S-collidine to pH 7 .4,
and processed as described previously (15). For cyto-
chemical localization of catalase, selected samples of
liver from treated and untreated animals were fixed
in 2.5% glutaraldehyde buffered with 0 .1 M sodium
cacodylate, pH 7.4, for 4 h at 4°C. After fixation, the
tissues were rinsed overnight in 0.1 M cacodylate
buffer containing 0.2 M sucrose. Then the tissues were
finely chopped with a Sorvall "chopper" (Ivan
Sorvall, Inc., Newtown, Conn.) and incubated at
37°C for 30-45 min in the 3',3'-diaminobenzidine
oxidation medium of Novikoff and Goldfischer (10)
and processed for electron microscope examination.
Assay of Liver Catalase Activity
After determining that nafenopin at 0.125% and
0.25% caused maximal proliferation of microbodies,
in both male and female animals, we limited the bio-
chemical studies of catalase to these two dietary levels.
The animals were killed by light ether anaesthesia
and the livers were removed and weighed . 5% liver
homogenates were prepared to which sodium deoxy-
cholate (DOC) was added to give a final DOC con-
centration of 0.5% (25) . This mixture was incubated
at room temperature for 30 min and then centrifuged
in a Spinco model L ultracentrifuge (Beckman Instru-
ments, Inc., Spinco Div., Palo Alto, Calif.) using a
50 rotor at 35,000 rpm for 85 min . After centrifuga-
tion the lipid-containing layer at the top was carefully
removed and the supernate was assayed for catalase
activity at 25 °C by the spectrophotometric method
described by Lück (26) . Total proteins were deter-
mined by the method of Lowry et al. (27) .
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strain) and acatalasemic (Csb strain) mice, immuno-
precipitation of protein reactive with antibody specific
for catalase was undertaken. The anticatalase serum
was obtained by injecting rabbits with catalase puri-
fied from the livers of Cs, strain mice. By the Ouch-
terlony double diffusion method, this antiserum gave
single precipitin lines with wild and acatalasemic liver
extracts.
The content of liver catalase protein in control and
nafenopin-treated wild type male and female mice
was determined by the immunotitration method
referred to above (25). Quantitation of liver catalase
protein in acatalasemic mice by the immunotitration
method could not be performed, because of low levels
of catalase activity (17, 28) and also because of rapid
inactivation of catalase when incubated at 37°C
(29). In order to compare the amount of catalase
protein in livers of acatalasemic and wild type mice,
equal amounts of liver extracts from normal and
nafenopin-treated animals were incubated with
quantities of antiserum that were found to neutralize
the catalase protein in normal and nafenopin-treated
wild type mice. The immunoprecipitates were cen-
trifuged and washed twice with cold 0.15 M sodium
chloride. The washed precipitates were dissolved in
0.1 M sodium hydroxide and the absorbance at 280
nm was measured.
Serum Cholesterol and Triglycerides
All animals were lightly anesthetized with ether .
Blood was collected from the inferior vena cava from
nonfasted animals between 9 and 10 a .m. Serum total
cholesterol and/or glyceride glycerol were determined
after quantitative separation on silicic acid from phos-
pholipids by the micromethod described by Azarnoff
(30) .
RESULTS
Studies in Rats
MICROBODY PROLIFERATION :
	
With
0.0125% of nafenopin for 2 wk, the liver weights
were only slightly increased . Nafenopin given at
0.125% and 0.25% produced a marked increase
in liver weights in both male and female rats
(Table I). Light microscope examination of these
livers revealed greatly enlarged hepatocytes con-
taining abundant acidophilic, finely granular
cytoplasm. During the initial states of nafenopin
treatment, numerous mitoses of liver cells were
encountered . Autoradiographic studies, after
['H]thymidine pulse, during the first week of
nafenopin administration showed numerous la-
beled hepatocyte nuclei in male and female rats .'
Quantitation of Liver Catalase Protein
IN RATS : Content of catalase protein in normal
and nafenopin-treated male and female rats was
determined by immunotitration method described by
Ganschow and Schimke (25).
IN WILD AND ACATALASEMIC MICE : In or-
der to determine the content of liver catalase protein
among control and nafenopin-treated wild type (Cs, 1 Reddy, J., and Prasad, J. Unpublished observations.TABLE I
Effect of Feeding F-344 Rats with Nafenopin on Liver Weight, Liver Catalase Activity, Serum
Cholesterol, and Serum Glyceride-Glycerol Concentrations
(0 .25%)
* Nafenopin was administered in ground Purina Chow for 4 wk .
$ Mean f standard error.
Increase in the number of microbody profiles
was evident in both sexes of rats given various
dietary concentrations of nafenopin. I-µm sections
of Epon-embedded material clearly suggested
that the increase in microbodies is generalized in
the cytoplasm of liver cells throughout the entire
liver lobule. With 0.0125% nafenopin, the micro-
body increase was slight when compared to the
degree of proliferation encountered with higher
dose levels. The microbody profiles were most
numerous in liver cells of male and female rats
(Fig. I) given 0.125% nafenopin. With 0.257,
nafenopin, there was no additional increase in
number of microbody profiles . The microbody
proliferation in both sexes of rats treated with
0.125 ,7 0 and 0.26 ,7 0 nafenopin was found to be of
the same magnitude . Prolonged treatment with
nafenopin resulted in the persistence of an in-
creased number of peroxisomal profiles in male
and female rats . Conspicuous variations in size
and shape of microbody profiles were apparent .
Nucleoids were observed in many microbody pro-
files of different sizes and configurations. Ab-
normalities in size and shape of peroxisomal pro-
files were striking in animals given 0.0125%
nafenopin. Several of these microbody profiles
contained striations in the matrix (Fig. 2), similar
to those seen in CPIB-treated animals (14). A
number of microbody profiles in liver cells of
animals on prolonged nafenopin treatment pos-
sessed a somewhat flocculent matrix . However,
all these organelles stained positively for catalase
when incubated in the alkaline 3',3'-diamino-
benzidine medium . This reaction was inhibited
when tissues were incubated in the presence of
aminotriazole.
In addition to showing microbody proliferation,
the liver cells of nafenopin-treated animals re-
vealed marked proliferation of smooth endoplas-
mic reticulum. Isolated channels of rough endo-
plasmic reticulum were also frequently encoun-
tered. Mitochondria appeared normal in size,
shape, and number. They did not show any in-
clusions or other obvious structural abnormality
(Fig. 1). There was no increase in the number of
lysosomes or lipid droplets in nafenopin-treated
livers. Many hepatocyte nucleoli were hyper-
trophied .
MICROBODY REVERSAL : Rats treated with
nafenopin for 6 wk showed increase in the number
of microbody profiles to the same extent as evi-
denced at 4 and 8 wk. Gradual depletion in the
number of microbody profiles was noted during
the first 7 days after withdrawal of nafenopin . By
14 days after the drug was discontinued, the num-
ber of microbody profiles returned to normal . The
reduction in microbody profiles was imperceptible
in that there was no appreciable evidence of cellu-
lar autophagy. Detailed examination of livers
during the first week of nafenopin withdrawal
revealed certain interesting morphological fea-
tures (Figs. 3-7). Marked decrease in electron
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Group*
No. of
animals Liver weight $
Liver catalase
activity $
Serum
cholesterol I
Serum glyceride-
glycerol$
g/100 g body weight U/mg protein mg/100 ml mg/100 ml
Male rats
Controls 6 3 .75 f 0.42 38.0 f 3 .9 82 f 5 10.6 f 2 .8
Nafenopin 5 8 .09 f 0 .52 74.9 f 5 .1 86 f 9 2 .9 f 0 .6
(0 .125%)
Nafenopin 6 8 .34 f 0.48 86.1 f 4.3 79 f 8 1 .6 f 0.2
(0 .25%)
Female rats
Controls 6 3 .21 f 0.36 31 .2 f 3 .7 76 f 4 9.7 f 2 .4
Nafenopin 4 7 .95 f 0.18 71 .4 f 4.2 66 f 4 2.5 f 0.3
(0 .125%)
Nafenopin 5 8.10 f 0.04 82 .7 f 1 .25 74 f 6 2 .3 f 0 .5FiauRE 1 Female rat liver . Nafenopin 0.125% in the diet for 4 wk. The microbody proliferation in
female rat liver cells was comparable to that observed in male rats . Significant variation in size and
shape of microbody profiles (mb) is evident. Nucleoids (n). X 14,500.
348opacity of the matrix was noted in some micro-
body profiles. Several dilated endoplasmic reticu-
lum channels contained crystalline microbody
nucleoids or cores (Figs. 3 and 4) without the
background matrix proteins, suggesting a gradual
depletion of matrix proteins presumably due to
cessation of synthesis after nafenopin withdrawal .
Extrusion of nucleoids into hyaloplasm was also
seen. At 7 days after withdrawal of nafenopin,
occasional examples of nucleoids lying free in the
hyaloplasm were also encountered (Figs. 6 and 7).
LIVER CATALASE : The results in Table I
indicate that the activity of catalase in the liver
in both male and female rats increased about two-
fold on administration of 0 .125% or 0.25% nafeno-
pin. When liver catalase activities were determined
in male rats treated with 0.25% nafenopin for
2-14 days, it was found that the activity of cata-
lase increases progressively, reaching the steady
state level in 8-12 days. Nafenopin appeared as
effective as CPIB in increasing the liver catalase
activity. It is of interest to note that the induced
steady state of catalase activity with these two
drugs is nearly the same, i.e. approximately twice
that of the normal steady state .
The results of immunotitration of liver catalase
in male and female rats treated with 0 .25%
nafenopin for 4 wk are shown in Fig . 8. The
amount of anticatalase serum needed to precipi-
tate completely the catalase activity from 1 ml of
5% liver extract of either male or female rat
treated with nafenopin was two times greater
than that required for extracts from livers of un-
treated controls . These results indicate that the
amount of catalase protein in liver extracts of
male and female rats given nafenopin was the
same and that nafenopin causes a twofold increase
in the amount of liver catalase protein when com-
pared to controls.
By 10 days after withdrawal of nafenopin from
the diet, the catalase activity in liver reverted to
normal values which paralleled the reduction in
the number of hepatic microbody profiles.
SERUM CHOLESTEROL AND SERUM GLYC-
ERIDE LEVELS : Administration of nafenopin
at 0.125% and 0.25% to both male and female
rats produced no significant cholesterol-lowering
effect at 4 wk . In direct contrast, however, a pro-
found reduction in serum glyceride levels was ob-
tained in both males and females (Table I) .
Within 7-10 days after withdrawal of the drug
the serum glyceride levels returned to normal,
which paralleled the reduction in catalase activity
and the number of microbody profiles .
Studies in Mice
MICROBODY PROLIFERATION : Nafenopin
was given to both sexes of wild type (Csa strain)
mice and acatalasemic (Csb strain) mice at dietary
levels of 0.125 0 / 0 and 0.25%. The gain in body
weight was not affected at 0.125 % dose level,
whereas at 0.25% level there was some reduction
in weight gain. However, at both these levels,
nafenopin produced a marked increase in the
weight of the liver in both males and females .
In wild type mice fed 0.125% nafenopin for 4-8
wk the liver weight was approximately 25% of
the body weight (Table II). Similar increases in
liver weight were also seen in both sexes of acatala-
semic mice treated with nafenopin . Examination
of these livers with the light microscope showed
large polygonal liver cells with abundant cyto-
plasm. Several mitotic figures were seen in the
livers of animals killed during the first 10 days of
nafenopin administration, suggesting that nafeno-
pin-induced increases in liver weight are due in
part to cell multiplication and cellular hyper-
trophy.
The microbody proliferation was most pro-
nounced in the livers of both sexes of wild type
and acatalasemic mice given 0 .125% nafenopin
(Fig. 9) . Further increase in the number of micro-
body profiles was not seen with the higher dose
level. In previous studies, we did not observe any
increase in the number of microbody profiles in
the female wild type (Csa strain) mice treated
with CPIB, although CPIB produced a marked in-
crease in hepatic microbody population in both
sexes of acatalasemic (Csb strain) mice (17) . The
absence of sex difference in microbody prolifera-
tion in response to nafenopin, in rats and mice,
is of particular interest .
The microbody profiles were numerous and
showed a great deal of variation in size and
shape. Continuities between adjacent microbody
profiles and between microbody profiles and
smooth endoplasmic reticulum channels were
noted frequently (Figs . 10 and 11) . Structural
changes in mitochondria were not seen, and
because of marked increase in microbody profiles,
the mitochondria appeared sparse. Proliferation
of smooth endoplasmic reticulum was observed
in the liver cells of all animals treated with nafeno-
pin.
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mination of catalase activity in livers of acatala-
semic and wild type mice are shown in Table II .
After nafenopin treatment, the catalase activity
in male and female wild type mice (Csa strain) was
significantly increased. The amount of catalase
protein in liver of untreated and treated Csa mice
was determined by the immunotitration method .
a06
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0.22
	
0.26
	
0.3
ml OF ANTICATALASE SERUM ADDED TO
I m l OF LIVER EXTRACT
FIGURE 8 Quantitation of liver catalase by immuno-
precipitation in male and female rats treated with
0.25% nafenopin for 4 wk. Increasing quantities of
anticatalase serum were added to 1-ml samples of
deoxycholate-treated liver extracts from normal
males (A-A), normal females (o-o), nafenopin-
treated males (A-A) and nafenopin-treated females
(0--0). Dashed lines are extrapolations of the linear
portions of the titration curves to zero catalase ac-
tivity.
0.02
For complete precipitation of the catalase activity
from I ml of 2.5% liver extract of Cs' mice treated
with nafenopin for 8 wk, approximately 0 .64 ml
of anticatalase serum was required, whereas only
0.31 ml antiserum was required to precipitate the
catalase activity from I ml of 2 .5% liver extracts
from untreated wild mice . From these findings it
can be reasonably assumed that a twofold increase
in concentration of catalase protein occurs in
livers of Csa mice treated with nafenopin.
Acatalasemic (Csb) mice treated with nafenopin
showed only a minimal increase in liver catalase
activity (Table II), although the microbody
population in liver cells was comparable to that
encountered in male and female wild type (Csa)
mice. Studies of Aebi et al. (29) demonstrated
that acatalasemic mutant mice have an unstable
catalase that is unusually heat labile. The catalase
in the present studies was assayed on liver extracts
treated earlier with DOC and kept at room tem-
perature for 30 min (see Materials and Methods) .
Accordingly, the low levels of catalase in nafeno-
pin-treated Csb mice may be, in part, due to in-
activation at room temperature.
To determine the quantity of catalase protein
in acatalasemic mice, 0 .31 ml and 0.64 ml of
anticatalase serum were added, respectively, to 1
ml samples of 2 .5% liver extracts from control
and nafenopin-treated animals . The amount of
anticatalase serum used was the same that was
found to precipitate all the catalase activity in
wild type mice by the immunotitration method
(see above). The amount of protein precipitated
from nafenopin-treated, acatalasemic mouse
liver extracts was approximately twice that pre-
cipitated from control mouse liver extracts . Fur-
thermore, the amounts of protein precipitated
FIGURE 2 Male rat treated with 0.0125% nafenopin for 2 wk. Several microbody profiles contained
striations in the matrix (arrows). Nucleoid (n). X 65,000.
FIGURES 3-7 Figures 3-7 are from the livers of male rats killed between 2 and 10 days after withdrawal
of nafenopin after they have been on the drug for 6 wk.
FIGURES 3-5 Microbody nucleoids (n) are seen within the irregular endoplasmic reticulum channels
within 5-7 days after discontinuation of nafenopin . Electron-opaque microbody proteins are not seen
in these membranes. In Fig. 3, the dumb-bell-shaped channel (arrow) contains a residue of electron-
opaque material similar to that present in the channel containing nucleoid, possibly suggesting that the
matrix proteins have dried up after withdrawal of nafenopin . Figs. 4 and 5. X 71,000. Fig. 3. X 49,000.
FIGURES 6 and 7 Nucleoids (n) are seen in the hyaloplasm . By 5-7 days after removal of nafenopin
from the diet, some microbody nucleoids were seen lying free in cytoplasm after dissociating from micro-
body profiles. X 52,000.
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TABLE II
Effect of Feeding Wild Type (Cs" Strain) Mice and Acatalasemic (Csb Strain) Mice with
Nafenopin on Liver Weight, Liver Catalase Activity, and Serum
Glyceride-Glycerol Levels .
* Nafenopin (0.125%) was given in ground Purina Chow for 8 wk .
from the liver extracts of acatalasemic and wild
type mice were also comparable . From these
results it can be assumed that nafenopin causes
approximately a twofold increase in the quantity
of liver catalase protein in acatalasemic mice .
SERUM GLYCERIDE LEVELS :
	
The results
listed in Table II indicate that serum glyceride-
glycerol levels are considerably lower in the
acatalasemic mice than in the wild type mice .
These findings in untreated controls are in agree-
ment with the observations of Goldfischer et al.
(31) . After treatment with 0 .1250 /, nafenopin for
8 wk, the serum glyceride levels in both sexes of
acatalasemic and wild type mice were markedly
lowered (Table II) . Serum cholesterol levels of
these mice were not determined in this study .
DISCUSSION
Unlike other cellular constituents, microbodies
(peroxisomes) in hepatic parenchymal cells are
infrequently altered in number or morphology by
experimental manipulations . However, markedly
reduced activities of catalase and/or other perox-
isomal enzymes in the liver have been observed in
certain conditions, particularly in tumor-bearing
animals (32). Quantitative studies to date indicate
that CPIB and acetylsalicylic acid are the only
known compounds that are capable of inducing
significant increase in the number of microbody
profiles in male rat liver cells and that the micro-
body proliferative response induced by CPIB is
more pronounced in comparison to that induced
by acetylsalicylic acid (14, 15, 33) . Concomitant
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with the increase in microbody profiles, the liver
catalase activity is increased twofold after CPIB
treatment due to enhanced synthesis of this
enzyme (21) . Additional studies by Svoboda,
Azarnoff, and Reddy (16) demonstrated that in
rats, CPIB-induced microbody proliferation and
rise in catalase levels are dependent, to a signifi-
cant degree, upon male sex hormones.
In the present study, microbody proliferation
in both male and female rats treated with higher
doses of nafenopin (0.125% and 0.25%) was very
pronounced . Marked increase in the number of
microbody profiles was also observed in both sexes
of wild type and acatalasemic mice given nafeno-
pin. The microbody proliferation induced with
0.125% nafenopin in these animals was of the
same degree as that induced by 0.25% CPIB
(14, 15, 17) . In addition, these studies have also
shown a twofold increase in the hepatic catalase
activity and in the amount of catalase protein
in both sexes of rats and wild type mice treated
with nafenopin. Although the increase in catalase
activity was not significant in acatalasemic mice
given nafenopin, the amount of liver catalase
protein in these animals was approximately equal
to that found in nafenopin-treated wild type mice.
Nafenopin, like CPIB, is a phenolic ether which
produces in rats a significant reduction in serum
triglycerides, but does not significantly reduce the
serum cholesterol (24). Serum glycerol-glycerides
were significantly lowered in rats and mice given
nafenopin in the present investigation . The studies
of Best and Duncan (24) indicate that somewhat
Group*
No. of
animals Liver weight
Liver catalase
activity
Serum glyceride-
glycerol
g1100 g body weight U/mg protein mg/100 ml
Wild type (Cs) mice
Males control 6 5 .3 f 0 .30 38 .8 f 3 .1 11 .6 t 1 .8
Males nafenopin 4 24 .6 t 2 .80 76 .3 t 5 .6 4 .2 t 0.4
Females control 5 4 .9 t 0 .26 37 .2 t 4 .3 10.5 t 1 .3
Females nafenopin 4 26 .5 f 1 .70 71
	
f 5 .4 4.1 t 0.6
Acatalasemic (CSb) Mice
Males control 6 5 .6 t 0 .25 10 .5 ± 3 .6 5 .7 t 1 .7
Males nafenopin 4 18 .7 t 1 .90 15.2 t 2 .7 1 .9 t 0 .6
Females control 4 5 .0 f 0 .40 11 .3 t 3 .2 5.3 f 2 .2
Females nafenopin 4 19 .8 f 2 .75 13 .4 f 2 .8 2 .1 f 0 .8FIGURE 9 Female wild type mouse (Cs' strain). Nafenopin 0.125% for 4 wk. Marked increase in number
of microbody profiles (mb) is seen. The microbody proliferation in male Cs' mice treated with nafenopin
was of similar magnitude. X 19,000.
353less than one-fifth as much nafenopin as CPIB
is required to produce similar degrees of hepato-
megaly and reduction in serum triglycerides in
rats. With 0.125 % and 0.25 % nafenopin, the liver
weights of rats in the present study were signifi-
cantly higher than in rats given 0 .25% CPIB (15) .
The hepatomegaly was most striking in wild type
and acatalasemic mice treated with 0.125%
nafenopin. In these animals, approximately 3 wk
of nafenopin administration resulted in massive
enlargement of livers, which accounted for one-
fifth to one-fourth of the total body weight. Pro-
longed treatment for 8 wk did not show significant
additional increase in liver weight. Although
microbody proliferation undoubtedly contributed
to hepatocellular hypertrophy in these animals,
preliminary studies using [5H]thymidine auto-
radiography suggest that nafenopin induces
hepatocellular proliferation during the initial
stages, resulting in an increase in liver cell popula-
tion, After the regenerative phase, the liver cells
appear to undergo marked hypertrophy (34).
Previous studies from this laboratory demon-
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FIGURES 10 and 11 Wild type male mouse. Nafenopin 0.125%, 8 wk. Microbody profiles (mb) con-
taining nucleoids are continuous with the smooth endoplasmic reticulum channels (arrows) . X 54,000.
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strated a distinct sex difference in microbody
proliferative response and in liver catalase induci-
bility in rats, C3H mice, and in wild type (Cs")
mice, after CPIB administration (15-17) . In fe-
males, CPIB failed to induce microbody prolifera-
tion and increase in liver catalase activity. How-
ever, when castrated female rats were given
testosterone propionate together with CPIB,
there was a marked increase in the number of
microbody profiles and in hepatic catalase activity
(16) . In the present study, however, in contrast
to the situation with CPIB, nafenopin induced
more or less similar degrees of microbody pro-
liferation and catalase induction in both sexes of
rats and wild type mice. Sex differences in the
metabolism of drugs and in the inducibility of
microsomal enzyme systems in rodent liver have
been established in several instances (35, 36) . The
reasons for this differential ability of CPIB and
nafenopin in inducing microbody proliferation
and catalase synthesis in male and female animals
can not be stated with certainty from these experi-
ments. Although CPIB and nafenopin are struc-turally similar hypolipidemic phenolic ethers,
there may exist differences in their metabolism .
It is possible that the microbody proliferative
effect of CPIB is dependent upon excessive ana-
bolic activity, whereas nafenopin may be less
dependent, or may possess androgenic activity.
The absence of sex difference in response to nafeno-
pin-induced microbody proliferation and catalase
synthesis may be due to the fact that this com-
pound is about five times more potent than clofi-
brate (CPIB) in producing hypotriglyceridemia
(23, 24). Further clarification would probably be
achieved by evaluation of the dose in relation to
reduction of plasma cholesterol and triglyceride
levels. It is not known if CPIB, in concentrations
greater than 0.25% in diet, would cause micro-
body proliferation in female rats and mice. This
may not occur in view of the finding that the
effect on lipids actually decreases when CPIB is
given in doses greater than 0 .25%. Despite the
uncertainty in understanding the basic differ-
ence(s) in the action of these drugs in inducing
microbody proliferation in one or both sexes of
rats and mice, the present study clearly identifies
nafenopin as an effective inducer of microbody
proliferation and of catalase synthesis in both
sexes.
In contrast to a sex difference in response to
CPIB in rats and mice cited above, no such
difference was observed in acatalasemic "mu-
tant" mice (17) . Both male and female acatala-
semic mice given CPIB showed profound increase
in number of hepatic microbody profiles. This
may be in part due to the genetic makeup of this
mutant mouse strain, because, within a given
species, genetic variation may be important in
determining the occurrence or magnitude of en-
zyme induction (35). Microbody proliferative
response in both sexes of acatalasemic mice after
nafenopin was identical to that obtained after
the administration of CPIB.
The increase in catalase activity and in the
amount of catalase protein in liver of rats treated
either with nafenopin or with CPIB was twice
that of controls. It is of interest to note that the
induced steady state of liver catalase in rats is
never more than twofold . Furthermore, even in
animals given diets containing both nafenopin
and CPIB, the concentration of liver catalase did
not exceed this level.' The amount of liver catalase
protein in these animals, therefore, does not
2 Reddy, J. Unpublished observations.
correspond with the severalfold increase in the
number of microbody profiles. Although, cyto-
chemically, catalase was demonstrable in all the
microbody profiles, the possibility that these
structures proliferating under the influence of
nafenopin or CPIB (37) possess a low concentra-
tion of catalase cannot be excluded . This is not
surprising in view of our earlier observation that
CPIB induces hepatic microbody proliferation in
animals treated with allylisopropylacetamide, a
drug which completely inhibits the catalase
synthesis (18) .
The relationship between the increase in the
number of hepatic microbody profiles and decrease
in serum cholesterol and/or triglycerides resulting
from the administration of CPIB and nafenopin,
is not clear. Despite numerous investigations, the
mechanism by which CPIB elicits the hypolipi-
demic and microbody proliferative responses
cannot be stated with certainty. Since nafenopin
is a relatively new compound in the expanding
field of hypolipidemic agents, studies dealing with
the mechanism of its action are lacking, because
it was withdrawn from clinical studies after it
was found to produce liver tumors in mice .' Re-
duction in serum glycerides and induction of
hepatic microbody proliferation and of catalase
appear to be the common properties of these two
drugs. Because of the significant increase in micro-
body population and in catalase activity resulting
from CPIB, Svoboda and Azarnoff (14) invoked
a possible relationship between CPIB-induced
microbody proliferation and hypolipidemia . A
similar relationship between microbodies and
lipid metabolism was suggested earlier by Novi-
koff and Shin (12) on the basis of the observation
of Hochstein and Ernster (38) that the rat liver
microsomes catalyze lipid peroxidation that can
lead to the production of hydrogen peroxide .
Administration of bovine hepatic catalase has
been shown to induce a hypocholesterolemic
response in humans and rabbits (39, 40) . More
recently, Goldfischer et al. (31) showed that in
acatalasemic mouse mutants the serum cholesterol
and triglycerides are significantly lower, suggest-
ing that in vivo peroxidase is responsible for hypo-
lipidemia. A definite relationship between in vivo
peroxidase and hypolipidemia in acatalasemic
mice appears doubtful because of the recent
'Wagner, W. E. CIBA Pharmaceuticals, personal
communication.
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genesis in this mutant strain (41).
In view of the reports dealing with the effect of
catalase on cholesterol, it appeared reasonable to
assume that the hypolipidemic effect of CPIB was
the result of endogenous elevation of liver catalase
produced by microbody proliferation (14). How-
ever, accumulated evidence indicates that the
hypolipidemic and microbody proliferative effects
of CPIB are possibly independent (15, 16, 18,
and 42). In the present study, the demonstration
of microbody proliferation and catalase induction
after administration of nafenopin, a potent hypo-
lipidemic drug, again raises the question of possible
relationship between microbody proliferation and
hypolipidemia. In this regard, it is also pertinent
to state that methyl clofenapate (43), a hypo-
Epidemic analogue of CPIB, also causes a very
significant hepatic microbody proliferation. On
an equivalent weight basis, methyl clofenapate
appears to be 5-10 times as potent as nafenopin
or CPIB in inducing microbody proliferation.
These drugs promise to be of considerable value
for studying the functional significance of micro-
body proliferation in the production of hypo-
chlesterolemia and hypotriglyceridemia. Further-
more, acetylsalicylic acid which induces micro-
body proliferation is also known to reduce serum
cholesterol levels (42). It is, therefore, necessary
to investigate the structural analogues of CPIB in
an attempt to determine the interrelationships of
chemical configuration of these drugs, microbody
proliferation, catalase induction, and hypolipi-
demia.
Although the role of drug-induced hepatic
microbody proliferation is not understood, the
widespread occurrence of microbodies in several
cell types of vertebrates has given rise to addi-
tional speculation regarding their functional
significance and has been the subject of discussion
in a recent symposium.4 In view of their wide-
spread distribution among tissues and species,
the possibility that microbodies may perform
different functions in different cell types cannot
be excluded, although their role in lipid metabo-
lism and in detoxification of H202 may be con-
sidered universal (13).
The observations on microbody profiles during
4 The symposium on "peroxisomes" organized by
The Histochemical Society on April 14, 1973, at its
24th annual meeting held in Atlantic City, N. J .
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recovery after withdrawal of nafenopin were
similar to those seen in rats after CPIB (44). DI.-
solution of the microbody matrix, appearance of
nucleoid cores in dilated endoplasmic reticulum
membranes or occasionally in the hyaloplasm,
are the significant findings. Incorporation of
microbody profiles into lysosomes or into auto-
phagocytic vacuoles was not detected. It appears
that cessation of enhanced synthesis of peroxisomal
proteins after discontinuation of nafenopin is
responsible for the reduction in the peroxisomal
protein pool. The reduction in number of micro-
body profiles appears to be due to progressively
diminishing quantities of peroxisomal matrix
proteins in endoplasmic reticulum channels.
Nafenopin was supplied by Dr. William E. Wagner,
CIBA Pharmaceuticals, Summit, N. J. Technical
assistance was given by Ms . Lynne Schmutz, Ms.
Faye Brady, Ms. Dianne Knox, Ms . Mary Ann
Wickham, and Mr. Charles Sittler. Mrs. Ella M.
Olson provided the editorial assistance.
This work was supported by United States Public
Health Service grants GM-15956 and CA-5680 .
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